tiprankstipranks
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
US Market
IDYA
IDEAYA Biosciences
RESEARCH TOOLSreports
Want to see IDYA full AI Analyst Report?

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

684 Followers
See the Price Targets and Ratings of:

IDYA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
IDEAYA
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$52.44
▲(25.56% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $52.44 with a high forecast of $62.00 and a low forecast of $42.00. The average price target represents a 25.56% change from the last price of $41.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","63":"$63","33.75":"$33.8","43.5":"$43.5","53.25":"$53.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.44444444444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,33.75,43.5,53.25,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.95,41.64615384615385,43.34230769230769,45.03846153846154,46.73461538461539,48.43076923076923,50.12692307692308,51.823076923076925,53.519230769230774,55.215384615384615,56.91153846153846,58.607692307692304,60.30384615384615,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.95,40.91111111111111,41.87222222222223,42.833333333333336,43.794444444444444,44.75555555555556,45.71666666666667,46.67777777777778,47.638888888888886,48.6,49.56111111111111,50.522222222222226,51.483333333333334,{"y":52.44444444444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.95,40.10769230769231,40.26538461538462,40.42307692307693,40.580769230769235,40.73846153846154,40.89615384615385,41.05384615384615,41.21153846153846,41.36923076923077,41.526923076923076,41.684615384615384,41.84230769230769,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.31,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.48,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.95,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$62.00Average Price Target$52.44Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on IDYA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$50
Buy
19.70%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Truist Financial Analyst forecast on IDYA
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on IDYA
Charles Zhu
LifeSci Capital
LifeSci Capital
$58
Buy
38.86%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Definium Therapeutics (NASDAQ: DFTX) and IDEAYA Biosciences (NASDAQ: IDYA)
Wedbush Analyst forecast on IDYA
Robert Driscoll
Wedbush
Wedbush
$60
Buy
43.64%
Upside
Reiterated
08/20/26
Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
Anupam Rama
J.P. Morgan
J.P. Morgan
$66→$62
Buy
48.43%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Spyre Therapeutics (NASDAQ: SYRE) and IDEAYA Biosciences (NASDAQ: IDYA)
Citizens JMP Analyst forecast on IDYA
Silvan Turkcan
Citizens JMP
Citizens JMP
$45→$42
Buy
0.55%
Upside
Reiterated
08/06/26
Ideaya Biosciences price target lowered to $42 from $45 at CitizensIdeaya Biosciences price target lowered to $42 from $45 at Citizens
Wells Fargo Analyst forecast on IDYA
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$48
Buy
14.92%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)
RBC Capital Analyst forecast on IDYA
Leonid Timashev
RBC Capital
RBC Capital
$48
Buy
14.92%
Upside
Reiterated
08/04/26
IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital
Guggenheim Analyst forecast on IDYA
Paul Jeng
Guggenheim
Guggenheim
$54
Buy
29.28%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on IDYA
Michael Yee
UBS
UBS
$50
Buy
19.70%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and IDEAYA Biosciences (NASDAQ: IDYA)
Goldman Sachs Analyst forecast on IDYA
Corinne Johnson
Goldman Sachs
Goldman Sachs
$35→$36
Hold
-13.81%
Downside
Reiterated
06/03/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Diaceutics (Other OTC: DIUXF)
TD Cowen Analyst forecast on IDYA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)
Citi Analyst forecast on IDYA
Yigal Nochomovitz
Citi
Citi
$65
Buy
55.61%
Upside
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Jefferies Analyst forecast on IDYA
Maury Raycroft
Jefferies
Jefferies
$31→$52
Buy
24.49%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Barclays Analyst forecast on IDYA
Peter Lawson
Barclays
Barclays
$40
Buy
-4.24%
Downside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on IDYA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$50
Buy
19.70%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Karyopharm Therapeutics (NASDAQ: KPTI)
Truist Financial Analyst forecast on IDYA
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
LifeSci Capital Analyst forecast on IDYA
Charles Zhu
LifeSci Capital
LifeSci Capital
$58
Buy
38.86%
Upside
Reiterated
08/31/26
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (NASDAQ: VOR), Definium Therapeutics (NASDAQ: DFTX) and IDEAYA Biosciences (NASDAQ: IDYA)
Wedbush Analyst forecast on IDYA
Robert Driscoll
Wedbush
Wedbush
$60
Buy
43.64%
Upside
Reiterated
08/20/26
Wedbush Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)
J.P. Morgan Analyst forecast on IDYA
Anupam Rama
J.P. Morgan
J.P. Morgan
$66→$62
Buy
48.43%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI), Spyre Therapeutics (NASDAQ: SYRE) and IDEAYA Biosciences (NASDAQ: IDYA)
Citizens JMP Analyst forecast on IDYA
Silvan Turkcan
Citizens JMP
Citizens JMP
$45→$42
Buy
0.55%
Upside
Reiterated
08/06/26
Ideaya Biosciences price target lowered to $42 from $45 at CitizensIdeaya Biosciences price target lowered to $42 from $45 at Citizens
Wells Fargo Analyst forecast on IDYA
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$48
Buy
14.92%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Buy Rating on IDEAYA Biosciences (IDYA)
RBC Capital Analyst forecast on IDYA
Leonid Timashev
RBC Capital
RBC Capital
$48
Buy
14.92%
Upside
Reiterated
08/04/26
IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital
Guggenheim Analyst forecast on IDYA
Paul Jeng
Guggenheim
Guggenheim
$54
Buy
29.28%
Upside
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on IDYA
Michael Yee
UBS
UBS
$50
Buy
19.70%
Upside
Reiterated
06/09/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and IDEAYA Biosciences (NASDAQ: IDYA)
Goldman Sachs Analyst forecast on IDYA
Corinne Johnson
Goldman Sachs
Goldman Sachs
$35→$36
Hold
-13.81%
Downside
Reiterated
06/03/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: IDEAYA Biosciences (NASDAQ: IDYA) and Diaceutics (Other OTC: DIUXF)
TD Cowen Analyst forecast on IDYA
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), IDEAYA Biosciences (IDYA)
Citi Analyst forecast on IDYA
Yigal Nochomovitz
Citi
Citi
$65
Buy
55.61%
Upside
Reiterated
04/13/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Jefferies Analyst forecast on IDYA
Maury Raycroft
Jefferies
Jefferies
$31→$52
Buy
24.49%
Upside
Reiterated
04/05/26
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), IDEAYA Biosciences (NASDAQ: IDYA) and Bristol-Myers Squibb (NYSE: BMY)
Barclays Analyst forecast on IDYA
Peter Lawson
Barclays
Barclays
$40
Buy
-4.24%
Downside
Reiterated
11/04/25
IDEAYA Biosciences (IDYA) Gets a Buy from Barclays
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
BLTEBelite Bio, Inc. ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

3 Months
Charles ZhuLifeSci Capital
Success Rate
19/30 ratings generated profit
63%
Average Return
+10.95%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 63.33% of your transactions generating a profit, with an average return of +10.95% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
26/30 ratings generated profit
87%
Average Return
+43.31%
Copying Charles Zhu's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +43.31% per trade.
2 Years
Charles ZhuLifeSci Capital
Success Rate
27/30 ratings generated profit
90%
Average Return
+57.65%
Copying Charles Zhu's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +57.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
27
25
16
17
9
Buy
10
4
4
11
12
Hold
1
3
2
2
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
32
22
30
21
In the current month, IDYA has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 52.44.
Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$1.18 with a range of -$1.42 to -$0.84. The previous quarter’s EPS was -$1.22. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.
Next quarter’s earnings estimate for IDYA is -$1.18 with a range of -$1.42 to -$0.84. The previous quarter’s EPS was -$1.22. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $6.84M with a range of $0.00 to $35.00M. The previous quarter’s sales results were $8.86M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.
Next quarter’s sales forecast for IDYA is $6.84M with a range of $0.00 to $35.00M. The previous quarter’s sales results were $8.86M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 52.44.
    What is IDYA’s upside potential, based on the analysts’ average price target?
    IDEAYA Biosciences has 25.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IDYA a Buy, Sell or Hold?
          IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is IDEAYA Biosciences’s price target?
            The average price target for IDEAYA Biosciences is 52.44. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $62.00 ,the lowest forecast is $42.00. The average price target represents 25.56% Increase from the current price of $41.77.
              What do analysts say about IDEAYA Biosciences?
              IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IDYA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.